What is clinical trial liability insurance and which biotechs need it?

Clinical trial liability insurance is dedicated coverage for bodily injury and death claims arising from human study subjects in pharmaceutical, biotech, or medical device clinical trials. It is required by FDA, IRBs, and most clinical trial agreements (CTAs) between sponsors, CROs, and sites.

Any biotech operator with an active IND and Phase 1, 2, or 3 clinical trials needs clinical trial liability coverage. For first-in-human studies of irreversible interventions (cell therapy, gene therapy, neurosurgical devices), $5M-$10M per trial sponsor-side is typical. Cell and gene therapy trials with FDA-mandated long-term follow-up registries require extended reporting period coverage through registry close - often 5-15 years post-dosing.

Multi-site international trials require coverage that satisfies each country's local insurance regulatory regime - many EU countries require admitted-paper local policies, which adds complexity and cost beyond US-only programs. The CRO or trial site can typically provide guidance on country-specific requirements; the sponsor-side biotech is responsible for ensuring the program satisfies them.